# OnCo record fianlimab-phase3-melanoma (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/fianlimab-phase3-melanoma/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "fianlimab-phase3-melanoma", "NCT05352672" ;
  schema:name "Fianlimab + cemiplimab phase 3 (first-line melanoma)"@en ;
  schema:description "A second LAG-3 blocker failed to beat pembrolizumab alone, a warning that the Opdualag result is not automatically a class effect."@en ;
  schema:url <https://onco.cc/trials/fianlimab-phase3-melanoma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05352672>, <https://investor.regeneron.com/news-releases/news-release-details/regeneron-provides-update-phase-3-trial-fianlimab-lag-3> ;
  onco:status "negative" ;
  onco:tag "failure", "lesson:class-effect-not-guaranteed" ;
  onco:phase "3" ;
  schema:startDate "2022-07-14" ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/advanced-melanoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/lag3/>, <https://onco.cc/targets/pd1/> ;
  onco:drugs <https://onco.cc/drugs/fianlimab/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/regeneron/> ;
  onco:trials <https://onco.cc/trials/relativity-047/> .